Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin

Is clonal hematopoiesis of indeterminate potential (CHIP) associated with increased risk of cardiovascular disease (CVD) events or clinically significant bleeding (CSB), and is there a differential effect of aspirin?In this prespecified secondary analysis of a randomized clinical trial including 9434 participants, CHIP was not associated with increased risk of CVD events, but was associated with an increased risk of CSB. No evidence was found that aspirin effects on CVD events and CSB were different for individuals with CHIP compared to those without.The data do not provide evidence that aspirin is beneficial for older individuals with CHIP in the setting of primary prevention.

Corresponding Author: Zoe K. McQuilten, MBBS, PhD, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, VIC 3004, Australia (zoe.mcquilten@monash.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.